Qaasid News

Download Our App

Category: 3. Business

  • Mesenchymal stem cells and extracellular vesicles for knee osteoarthritis: clinical application, mechanism exploration and prospect | Stem Cell Research & Therapy

    Mesenchymal stem cells and extracellular vesicles for knee osteoarthritis: clinical application, mechanism exploration and prospect | Stem Cell Research & Therapy

  • Gelber AC. Knee osteoarthritis. Ann Intern Med. 2024;177(9):ITC129–129144.

    Google Scholar 

  • Yang G, Wang J, Liu Y, et al. Burden of knee osteoarthritis in 204 countries and Territories, 1990–2019: results from the global burden of disease study 2019. Arthritis Care Res (Hoboken). 2023;75(12):2489–500.

    Google Scholar 

  • Li E, Tan J, Xu K, Pan Y, Xu P. Global burden and socioeconomic impact of knee osteoarthritis: a comprehensive analysis. Front Med (Lausanne). 2024;11:1323091.

    Google Scholar 

  • Katz JN, Arant KR, Loeser RF. Diagnosis and treatment of hip and knee osteoarthritis: A review. JAMA. 2021;325(6):568–78.

    Google Scholar 

  • Moore RA, Moore OA, Derry S, Peloso PM, Gammaitoni AR, Wang H. Responder analysis for pain relief and numbers needed to treat in a meta-analysis of Etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice. Ann Rheum Dis. 2010;69(2):374–9.

    Google Scholar 

  • Osani MC, Vaysbrot EE, Zhou M, McAlindon TE, Bannuru RR. Duration of symptom relief and early trajectory of adverse events for oral nonsteroidal antiinflammatory drugs in knee osteoarthritis: A systematic review and Meta-Analysis. Arthritis Care Res (Hoboken). 2020;72(5):641–51.

    Google Scholar 

  • Jones IA, Togashi R, Wilson ML, Heckmann N, Vangsness CT Jr. Intra-articular treatment options for knee osteoarthritis. Nat Rev Rheumatol. 2019;15(2):77–90.

    Google Scholar 

  • Berkovic D, Vallance P, Harris IA, et al. A systematic review and meta-analysis of short-stay programmes for total hip and knee replacement, focusing on safety and optimal patient selection. BMC Med. 2023;21(1):511.

    Google Scholar 

  • Vervullens S, Meert L, Smeets R, et al. Preoperative glycaemic control, number of pain locations, structural knee damage, self-reported central sensitisation, satisfaction and personal control are predictive of 1-year postoperative pain, and change in pain from pre- to 1-year posttotal knee arthroplasty. Knee Surg Sports Traumatol Arthrosc. 2025;33(1):201–19.

    Google Scholar 

  • Ulivi M, Orlandini L, D’Errico M, et al. Medium-term patient’s satisfaction after primary total knee arthroplasty: enhancing prediction for improved care. Orthop Traumatol Surg Res. 2024;110(2):103734.

    Google Scholar 

  • Viswanathan S, Shi Y, Galipeau J, et al. Mesenchymal stem versus stromal cells: international society for cell & gene therapy (ISCT®) mesenchymal stromal cell committee position statement on nomenclature. Cytotherapy. 2019;21(10):1019–24.

    Google Scholar 

  • Zhou J, Shi Y. Mesenchymal stem/stromal cells (MSCs): origin, immune regulation, and clinical applications. Cell Mol Immunol. 2023;20(6):555–7.

    Google Scholar 

  • Hoang DM, Pham PT, Bach TQ, et al. Stem cell-based therapy for human diseases. Signal Transduct Target Ther. 2022;7(1):272.

    Google Scholar 

  • Meng Z, He D, Wang H, et al. Mapping the knowledge landscape of and emerging future trends in stem cell therapy for osteoarthritis: A bibliometric analysis of the literature from 1998 to 2024. J Multidiscip Healthc. 2025;18:1281–95.

    Google Scholar 

  • Zhou C, Zhang B, Yang Y, et al. Stem cell-derived exosomes: emerging therapeutic opportunities for wound healing. Stem Cell Res Ther. 2023;14(1):107.

    Google Scholar 

  • Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002;2(8):569–79.

    Google Scholar 

  • Jeppesen DK, Fenix AM, Franklin JL, et al. Reassessment Exosome Composition Cell. 2019;177(2):428–e44518.

    Google Scholar 

  • Zou J, Yang W, Cui W, et al. Therapeutic potential and mechanisms of mesenchymal stem cell-derived exosomes as bioactive materials in tendon-bone healing. J Nanobiotechnol. 2023;21(1):14.

    Google Scholar 

  • Yáñez-Mó M, Siljander PR, Andreu Z, et al. Biological properties of extracellular vesicles and their physiological functions. J Extracell Vesicles. 2015;4:27066.

    Google Scholar 

  • Zeng Z, Zhou X, Wang Y, et al. Mitophagy-A new target of bone disease. Biomolecules. 2022;12(10):1420.

    Google Scholar 

  • Zeng B, Li Y, Khan N, et al. Yin-Yang: two sides of extracellular vesicles in inflammatory diseases. J Nanobiotechnol. 2024;22(1):514.

    Google Scholar 

  • Kolasinski SL, Neogi T, Hochberg MC, et al. 2019 American college of Rheumatology/Arthritis foundation guideline for the management of osteoarthritis of the Hand, Hip, and knee. Arthritis Rheumatol. 2020;72(2):220–33.

    Google Scholar 

  • Sharma L. Osteoarthritis of the knee. N Engl J Med. 2021;384(1):51–9.

    Google Scholar 

  • Hardingham T. Chondroitin sulfate and joint disease. Osteoarthr Cartil. 1998;6(Suppl A):3–5.

  • Tuan RS, Chen AF, Klatt BA. Cartilage regeneration. J Am Acad Orthop Surg. 2013;21(5):303–11.

    Google Scholar 

  • Guilak F, Nims RJ, Dicks A, Wu CL, Meulenbelt I. Osteoarthritis as a disease of the cartilage pericellular matrix. Matrix Biol. 2018;71–72:40–50.

    Google Scholar 

  • Yunus M, Nordin A, Kamal H. Pathophysiological perspective of osteoarthritis. Med (Kaunas). 2020;56(11):614.

    Google Scholar 

  • Peng Z, Sun H, Bunpetch V, et al. The regulation of cartilage extracellular matrix homeostasis in joint cartilage degeneration and regeneration. Biomaterials. 2021;268:120555.

    Google Scholar 

  • Yang CY, Chanalaris A, Troeberg L. ADAMTS and ADAM metalloproteinases in osteoarthritis – looking beyond the ‘usual suspects’. Osteoarthritis Cartilage. 2017;25(7):1000–9.

    Google Scholar 

  • Sang W, Xue S, Jiang Y, et al. METTL3 involves the progression of osteoarthritis probably by affecting ECM degradation and regulating the inflammatory response. Life Sci. 2021;278:119528.

    Google Scholar 

  • Coryell PR, Diekman BO, Loeser RF. Mechanisms and therapeutic implications of cellular senescence in osteoarthritis. Nat Rev Rheumatol. 2021;17(1):47–57.

    Google Scholar 

  • Lieberthal J, Sambamurthy N, Scanzello CR. Inflammation in joint injury and post-traumatic osteoarthritis. Osteoarthritis Cartilage. 2015;23(11):1825–34.

    Google Scholar 

  • Haraden CA, Huebner JL, Hsueh MF, Li YJ, Kraus VB. Synovial fluid biomarkers associated with osteoarthritis severity reflect macrophage and neutrophil related inflammation. Arthritis Res Ther. 2019;21(1):146.

    Google Scholar 

  • Caron MM, Emans PJ, Coolsen MM, et al. Redifferentiation of dedifferentiated human articular chondrocytes: comparison of 2D and 3D cultures. Osteoarthritis Cartilage. 2012;20(10):1170–8.

    Google Scholar 

  • van Gastel N, Stegen S, Eelen G, et al. Lipid availability determines fate of skeletal progenitor cells via SOX9. Nature. 2020;579(7797):111–7.

    Google Scholar 

  • Jouan Y, Bouchemla Z, Bardèche-Trystram B, et al. Lin28a induces SOX9 and chondrocyte reprogramming via HMGA2 and blunts cartilage loss in mice. Sci Adv. 2022;8(34):eabn3106.

    Google Scholar 

  • Liu Y, Xie HQ, Shen B. Type H vessels-a Bridge connecting subchondral bone remodelling and articular cartilage degeneration in osteoarthritis development. Rheumatology (Oxford). 2023;62(4):1436–44.

    Google Scholar 

  • Kahle ER, Patel N, Sreenivasappa HB, Marcolongo MS, Han L. Targeting cell-matrix interface mechanobiology by integrating AFM with fluorescence microscopy. Prog Biophys Mol Biol. 2022;176:67–81.

    Google Scholar 

  • Jia Y, Wang A, Zhao B, et al. An optimized method for obtaining clinical-grade specific cell subpopulations from human umbilical cord-derived mesenchymal stem cells. Cell Prolif. 2022;55(10):e13300.

    Google Scholar 

  • Montemurro T, Lavazza C, Montelatici E, et al. Off-the-Shelf Cord-Blood mesenchymal stromal cells: Production, quality Control, and clinical use. Cells. 2024;13(12):1066.

    Google Scholar 

  • Matas J, García C, Poblete D, et al. A phase I Dose-Escalation clinical trial to assess the safety and efficacy of umbilical Cord-Derived mesenchymal stromal cells in knee osteoarthritis. Stem Cells Transl Med. 2024;13(3):193–203.

    Google Scholar 

  • Chen CF, Hu CC, Wu CT, et al. Treatment of knee osteoarthritis with intra-articular injection of allogeneic adipose-derived stem cells (ADSCs) ELIXCYTE®: a phase I/II, randomized, active-control, single-blind, multiple-center clinical trial. Stem Cell Res Ther. 2021;12(1):562.

    Google Scholar 

  • Lee WS, Kim HJ, Kim KI, Kim GB, Jin W. Intra-Articular injection of autologous adipose Tissue-Derived mesenchymal stem cells for the treatment of knee osteoarthritis: A phase IIb, Randomized, Placebo-Controlled clinical trial. Stem Cells Transl Med. 2019;8(6):504–11.

    Google Scholar 

  • Emadedin M, Labibzadeh N, Liastani MG, et al. Intra-articular implantation of autologous bone marrow-derived mesenchymal stromal cells to treat knee osteoarthritis: a randomized, triple-blind, placebo-controlled phase 1/2 clinical trial. Cytotherapy. 2018;20(10):1238–46.

    Google Scholar 

  • Lee BW, Lee JJ, Jung JY, Ju JH. Intra-Articular injection of human bone Marrow-Derived mesenchymal stem cells in knee osteoarthritis: A Randomized, Double-Blind, controlled trial. Cell Transpl. 2025;34:9636897241303275.

    Google Scholar 

  • Figueroa-Valdés AI, Luz-Crawford P, Herrera-Luna Y, et al. Clinical-grade extracellular vesicles derived from umbilical cord mesenchymal stromal cells: preclinical development and first-in-human intra-articular validation as therapeutics for knee osteoarthritis. J Nanobiotechnol. 2025;23(1):13.

    Google Scholar 

  • Wang Y, Kong Y, Du J, et al. Injection of human umbilical cord mesenchymal stem cells exosomes for the treatment of knee osteoarthritis: from preclinical to clinical research. J Transl Med. 2025;23(1):641.

    Google Scholar 

  • Copp G, Robb KP, Viswanathan S. Culture-expanded mesenchymal stromal cell therapy: does it work in knee osteoarthritis? A pathway to clinical success. Cell Mol Immunol. 2023;20(6):626–50.

    Google Scholar 

  • Wang X, Ouyang L, Chen W, Cao Y, Zhang L. Efficient expansion and delayed senescence of hUC-MSCs by microcarrier-bioreactor system. Stem Cell Res Ther. 2023;14(1):284.

    Google Scholar 

  • Yue S, Zhai G, Zhao S, et al. The biphasic role of the infrapatellar fat pad in osteoarthritis. Biomed Pharmacother. 2024;179:117364.

    Google Scholar 

  • Taheri S, Yoshida T, Böker KO, et al. Investigating the microchannel architectures inside the subchondral bone in relation to estimated hip reaction forces on the human femoral head. Calcif Tissue Int. 2021;109(5):510–24.

    Google Scholar 

  • Warmink K, Rios JL, Varderidou-Minasian S, et al. Mesenchymal stem/stromal cells-derived extracellular vesicles as a potentially more beneficial therapeutic strategy than MSC-based treatment in a mild metabolic osteoarthritis model. Stem Cell Res Ther. 2023;14(1):137.

    Google Scholar 

  • Giorgino R, Albano D, Fusco S, Peretti GM, Mangiavini L, Messina C. Knee osteoarthritis: Epidemiology, Pathogenesis, and mesenchymal stem cells: what else is new? An update. Int J Mol Sci. 2023;24(7):6405.

    Google Scholar 

  • Manferdini C, Maumus M, Gabusi E, et al. Adipose-derived mesenchymal stem cells exert antiinflammatory effects on chondrocytes and synoviocytes from osteoarthritis patients through prostaglandin E2. Arthritis Rheum. 2013;65(5):1271–81.

    Google Scholar 

  • Yang G, Fan X, Liu Y, et al. Immunomodulatory mechanisms and therapeutic potential of mesenchymal stem cells. Stem Cell Rev Rep. 2023;19(5):1214–31.

    Google Scholar 

  • Xu L, Wu Y, Xiong Z, Zhou Y, Ye Z, Tan WS. Mesenchymal stem cells reshape and provoke proliferation of articular chondrocytes by paracrine secretion. Sci Rep. 2016;6:32705.

    Google Scholar 

  • Pers YM, Ruiz M, Noël D, Jorgensen C. Mesenchymal stem cells for the management of inflammation in osteoarthritis: state of the Art and perspectives. Osteoarthritis Cartilage. 2015;23(11):2027–35.

    Google Scholar 

  • Chen X, McClurg A, Zhou GQ, McCaigue M, Armstrong MA, Li G. Chondrogenic differentiation alters the immunosuppressive property of bone marrow-derived mesenchymal stem cells, and the effect is partially due to the upregulated expression of B7 molecules. Stem Cells. 2007;25(2):364–70.

    Google Scholar 

  • Liu H, Kemeny DM, Heng BC, Ouyang HW, Melendez AJ, Cao T. The immunogenicity and Immunomodulatory function of osteogenic cells differentiated from mesenchymal stem cells. J Immunol. 2006;176(5):2864–71.

    Google Scholar 

  • Liu B, Zhang M, Zhao J, Zheng M, Yang H. Imbalance of M1/M2 macrophages is linked to severity level of knee osteoarthritis. Exp Ther Med. 2018;16(6):5009–14.

    Google Scholar 

  • Xie J, Huang Z, Yu X, Zhou L, Pei F. Clinical implications of macrophage dysfunction in the development of osteoarthritis of the knee. Cytokine Growth Factor Rev. 2019;46:36–44.

    Google Scholar 

  • Zhao X, Zhao Y, Sun X, Xing Y, Wang X, Yang Q. Immunomodulation of MSCs and MSC-Derived extracellular vesicles in osteoarthritis. Front Bioeng Biotechnol. 2020;8:575057.

    Google Scholar 

  • Li P, Lv S, Jiang W, et al. Exosomes derived from umbilical cord mesenchymal stem cells protect cartilage and regulate the polarization of macrophages in osteoarthritis. Ann Transl Med. 2022;10(18):976.

    Google Scholar 

  • Li K, Yan G, Huang H, et al. Anti-inflammatory and Immunomodulatory effects of the extracellular vesicles derived from human umbilical cord mesenchymal stem cells on osteoarthritis via M2 macrophages. J Nanobiotechnol. 2022;20(1):38.

    Google Scholar 

  • Zhou H, Shen X, Yan C, et al. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells alleviate osteoarthritis of the knee in mice model by interacting with METTL3 to reduce m6A of NLRP3 in macrophage. Stem Cell Res Ther. 2022;13(1):322.

    Google Scholar 

  • Tian G, Yin H, Zheng J, et al. Promotion of osteochondral repair through immune microenvironment regulation and activation of endogenous chondrogenesis via the release of apoptotic vesicles from donor MSCs. Bioact Mater. 2024;41:455–70.

    Google Scholar 

  • Li Z, Li Q, Tong K, et al. BMSC-derived exosomes promote tendon-bone healing after anterior cruciate ligament reconstruction by regulating M1/M2 macrophage polarization in rats. Stem Cell Res Ther. 2022;13(1):295.

    Google Scholar 

  • Li B, Shen E, Wu Z, et al. BMSC-derived exosomes attenuate rat osteoarthritis by regulating macrophage polarization through PINK1/parkin signaling pathway. Cartilage. 2024:19476035241245805.

  • Sun W, Qu S, Ji M, Sun Y, Hu B. BMP-7 modified exosomes derived from synovial mesenchymal stem cells attenuate osteoarthritis by M2 polarization of macrophages. Heliyon. 2023;9(9):e19934.

    Google Scholar 

  • Zhang S, Chuah SJ, Lai RC, Hui J, Lim SK, Toh WS. MSC exosomes mediate cartilage repair by enhancing proliferation, attenuating apoptosis and modulating immune reactivity. Biomaterials. 2018;156:16–27.

    Google Scholar 

  • Cosenza S, Toupet K, Maumus M, et al. Mesenchymal stem cells-derived exosomes are more immunosuppressive than microparticles in inflammatory arthritis. Theranostics. 2018;8(5):1399–410.

    Google Scholar 

  • Sankaranarayanan J, Lee SC, Kim HK, Kang JY, Kuppa SS, Seon JK. Cinnamaldehyde-Treated bone marrow Mesenchymal-Stem-Cell-Derived exosomes via aqueous Two-Phase system attenuate IL-1β-Induced inflammation and catabolism via modulation of Proinflammatory signaling pathways. Int J Mol Sci. 2024;25(13):7263.

    Google Scholar 

  • Zhou L, Ye H, Liu L, Chen Y. Human bone mesenchymal stem Cell-Derived exosomes inhibit IL-1β-Induced inflammation in osteoarthritis chondrocytes. Cell J. 2021;23(4):485–94.

    Google Scholar 

  • Dong J, Li L, Fang X, Zang M, Exosome-Encapsulated. microRNA-127-3p released from bone Marrow-Derived mesenchymal stem cells alleviates osteoarthritis through regulating CDH11-Mediated Wnt/β-Catenin pathway. J Pain Res. 2021;14:297–310.

    Google Scholar 

  • Haghwerdi F, Khozaei Ravari M, Taghiyar L, et al. Application of bone and cartilage extracellular matrices in articular cartilage regeneration. Biomed Mater. 2021;16(4).

  • Harrell CR, Markovic BS, Fellabaum C, Arsenijevic A, Volarevic V. Mesenchymal stem cell-based therapy of osteoarthritis: current knowledge and future perspectives. Biomed Pharmacother. 2019;109:2318–26.

    Google Scholar 

  • Chen X, Shi Y, Xue P, Ma X, Li J, Zhang J. Mesenchymal stem cell-derived Exosomal microRNA-136-5p inhibits chondrocyte degeneration in traumatic osteoarthritis by targeting ELF3. Arthritis Res Ther. 2020;22(1):256.

    Google Scholar 

  • Tang S, Chen P, Zhang H, et al. Comparison of curative effect of human umbilical Cord-Derived mesenchymal stem cells and their small extracellular vesicles in treating osteoarthritis. Int J Nanomed. 2021;16:8185–202.

    Google Scholar 

  • Liu Y, Zeng Y, Si HB, Tang L, Xie HQ, Shen B. Exosomes derived from human Urine-Derived stem cells overexpressing miR-140-5p alleviate knee osteoarthritis through downregulation of VEGFA in a rat model. Am J Sports Med. 2022;50(4):1088–105.

    Google Scholar 

  • Wang Z, Yan K, Ge G, et al. Exosomes derived from miR-155-5p-overexpressing synovial mesenchymal stem cells prevent osteoarthritis via enhancing proliferation and migration, attenuating apoptosis, and modulating extracellular matrix secretion in chondrocytes. Cell Biol Toxicol. 2021;37(1):85–96.

    Google Scholar 

  • Hunziker EB, Quinn TM, Häuselmann HJ. Quantitative structural organization of normal adult human articular cartilage. Osteoarthritis Cartilage. 2002;10(7):564–72.

    Google Scholar 

  • Zhu Q, Yin F, Qin J, et al. Procr(+) chondroprogenitors sense mechanical stimuli to govern articular cartilage maintenance and regeneration. Cell. 2025;188(19):5194–e21116.

    Google Scholar 

  • Maenohara Y, Chijimatsu R, Tachibana N, et al. Lubricin contributes to homeostasis of articular cartilage by modulating differentiation of superficial zone cells. J Bone Min Res. 2021;36(4):792–802.

    Google Scholar 

  • Zhi Z, Zhang C, Kang J, et al. The therapeutic effect of bone marrow-derived mesenchymal stem cells on osteoarthritis is improved by the activation of the KDM6A/SOX9 signaling pathway caused by exposure to hypoxia. J Cell Physiol. 2020;235(10):7173–82.

    Google Scholar 

  • Li Q, Yu H, Sun M, et al. The tissue origin effect of extracellular vesicles on cartilage and bone regeneration. Acta Biomater. 2021;125:253–66.

    Google Scholar 

  • Chen S, Tang Y, Liu Y, et al. Exosomes derived from miR-375-overexpressing human adipose mesenchymal stem cells promote bone regeneration. Cell Prolif. 2019;52(5):e12669.

    Google Scholar 

  • Zhang S, Jin Z. Bone mesenchymal stem cell-derived extracellular vesicles containing long noncoding RNA NEAT1 relieve osteoarthritis. Oxid Med Cell Longev. 2022;2022:5517648.

  • Ye P, Mi Z, Wei D, Gao P, Ma M, Yang H. miR-3960 from mesenchymal stem cell-derived extracellular vesicles inactivates SDC1/Wnt/β-catenin axis to relieve chondrocyte injury in osteoarthritis by targeting PHLDA2. Stem Cells Int. 2022;2022:9455152.

  • Mao G, Zhang Z, Hu S, et al. Exosomes derived from miR-92a-3p-overexpressing human mesenchymal stem cells enhance chondrogenesis and suppress cartilage degradation via targeting WNT5A. Stem Cell Res Ther. 2018;9(1):247.

    Google Scholar 

  • Zhang B, Tian X, Qu Z, Hao J, Zhang W. Hypoxia-Preconditioned extracellular vesicles from mesenchymal stem cells improve cartilage repair in osteoarthritis. Membr (Basel). 2022;12(2):225.

    Google Scholar 

  • Rong Y, Zhang J, Jiang D, et al. Hypoxic pretreatment of small extracellular vesicles mediates cartilage repair in osteoarthritis by delivering miR-216a-5p. Acta Biomater. 2021;122:325–42.

    Google Scholar 

  • Hu J, Shi ZS, Liu XZ, et al. Exosomes derived from Runx2-overexpressing BMSCs enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rabbit model. Stem Cells Int. 2022;2022:6865041.

  • Li F, Xu Z, Xie Z, et al. Adipose mesenchymal stem cells-derived exosomes alleviate osteoarthritis by transporting MicroRNA – 376c-3p and targeting the WNT-beta-catenin signaling axis. Apoptosis. 2023;28(3–4):362–78.

    Google Scholar 

  • Xin Y, Wang YM, Zhang H, et al. Aging adversely impacts biological properties of human bone marrow-derived mesenchymal stem cells: implications for tissue engineering heart valve construction. Artif Organs. 2010;34(3):215–22.

    Google Scholar 

  • Diekman BO, Loeser RF. Aging and the emerging role of cellular senescence in osteoarthritis. Osteoarthritis Cartilage. 2024;32(4):365–71.

    Google Scholar 

  • Xie J, Wang Y, Lu L, et al. Cellular senescence in knee osteoarthritis: molecular mechanisms and therapeutic implications. Ageing Res Rev. 2021;70:101413.

    Google Scholar 

  • Cao H, Chen M, Cui X, et al. Cell-Free osteoarthritis treatment with Sustained-Release of Chondrocyte-Targeting exosomes from umbilical Cord-Derived mesenchymal stem cells to rejuvenate aging chondrocytes. ACS Nano. 2023;17(14):13358–76.

    Google Scholar 

  • Lei Q, Gao F, Liu T, et al. Extracellular vesicles deposit PCNA to rejuvenate aged bone marrow-derived mesenchymal stem cells and slow age-related degeneration. Sci Transl Med. 2021;13(578):eaaz8697. [pii].

    Google Scholar 

  • Gorgun C, Africano C, Ciferri MC, et al. Preconditioned mesenchymal stromal Cell-Derived extracellular vesicles (EVs) counteract inflammaging. Cells. 2022;11(22):3695.

    Google Scholar 

  • Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518–36.

    Google Scholar 

  • Iqbal Z, Rehman K, Xia J, et al. Biomaterial-assisted targeted and controlled delivery of CRISPR/Cas9 for precise gene editing. Biomater Sci. 2023;11(11):3762–83.

    Google Scholar 

  • Duan L, Xu L, Xu X, et al. Exosome-mediated delivery of gene vectors for gene therapy. Nanoscale. 2021;13(3):1387–97.

    Google Scholar 

  • Feng K, Liu J, Gong L, et al. Engineered MSC-sEVs as a versatile nanoplatform for enhanced osteoarthritis treatment via targeted elimination of senescent chondrocytes and maintenance of cartilage matrix metabolic homeostasis. Adv Sci (Weinh). 2025;12(8):e2413759.

    Google Scholar 

  • Long L, Zou G, Cheng Y, Li F, Wu H, Shen Y. MATN3 delivered by exosome from synovial mesenchymal stem cells relieves knee osteoarthritis: evidence from in vitro and in vivo studies. J Orthop Translat. 2023;41:20–32.

    Google Scholar 

  • Tao SC, Yuan T, Zhang YL, Yin WJ, Guo SC, Zhang CQ. Exosomes derived from miR-140-5p-overexpressing human synovial mesenchymal stem cells enhance cartilage tissue regeneration and prevent osteoarthritis of the knee in a rat model. Theranostics. 2017;7(1):180–95.

    Google Scholar 

  • Liu X, Rong N, Tian Z, et al. Acoustothermal transfection for cell therapy. Sci Adv. 2024;10(16):eadk1855.

    Google Scholar 

  • Zhu S, Xuan J, Shentu Y, et al. Effect of chitin-architected Spatiotemporal three-dimensional culture microenvironments on human umbilical cord-derived mesenchymal stem cells. Bioact Mater. 2024;35:291–305.

    Google Scholar 

  • Chen JG, Zhang EC, Wan YY, Huang TY, Wang YC, Jiang HY. Engineered hsa-miR-455-3p-Abundant extracellular vesicles derived from 3D-Cultured adipose mesenchymal stem cells for Tissue-Engineering hyaline cartilage regeneration. Adv Healthc Mater. 2024;13(18):e2304194.

    Google Scholar 

  • Yan L, Li D, Li S, et al. Exosomes derived from 3D-cultured MSCs alleviate knee osteoarthritis by promoting M2 macrophage polarization through miR-365a-5p and inhibiting TLR2/Myd88/NF-κB pathway. Chem Eng J. 2024;497:154432.

    Google Scholar 

  • Liu W, Li L, Rong Y, et al. Hypoxic mesenchymal stem cell-derived exosomes promote bone fracture healing by the transfer of miR-126. Acta Biomater. 2020;103:196–212.

    Google Scholar 

  • Zhen G, Wen C, Jia X, et al. Inhibition of TGF-β signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat Med. 2013;19(6):704–12.

    Google Scholar 

  • Pang L, Jin H, Lu Z, et al. Treatment with mesenchymal stem Cell-Derived Nanovesicle-Containing gelatin methacryloyl hydrogels alleviates osteoarthritis by modulating chondrogenesis and macrophage polarization. Adv Healthc Mater. 2023;12(17):e2300315.

    Google Scholar 

  • Guo S, Debbi L, Zohar B, et al. Stimulating extracellular vesicles production from engineered tissues by mechanical forces. Nano Lett. 2021;21(6):2497–504.

    Google Scholar 

  • Wang P, Zhao H, Chen W, et al. Cell-free osteoarthritis treatment with dual-engineered chondrocyte-targeted extracellular vesicles derived from mechanical loading primed mesenchymal stem cells. J Tissue Eng. 2025;16:20417314241312563.

    Google Scholar 

  • Lu M, Lou A, Gao J, et al. Quercetin-primed MSC exosomes synergistically attenuate osteoarthritis progression. J Orthop Surg Res. 2025;20(1):373.

    Google Scholar 

  • Kao TW, Liu YS, Yang CY, Lee OK. Mechanotransduction of mesenchymal stem cells and hemodynamic implications. Chin J Physiol. 2023;66(2):55–64.

    Google Scholar 

  • Skibber MA, Olson SD, Prabhakara KS, Gill BS, Cox CS Jr. Enhancing mesenchymal stromal cell potency: inflammatory licensing via mechanotransduction. Front Immunol. 2022;13:874698.

    Google Scholar 

  • Colombini A, Ragni E, Mortati L, et al. Adipose-Derived mesenchymal stromal cells treated with Interleukin 1 beta produced Chondro-Protective vesicles able to fast penetrate in cartilage. Cells. 2021;10(5):1180.

    Google Scholar 

  • Kim M, Shin DI, Choi BH, Min BH. Exosomes from IL-1β-Primed mesenchymal stem cells inhibited IL-1β- and TNF-α-Mediated inflammatory responses in Osteoarthritic SW982 cells. Tissue Eng Regen Med. 2021;18(4):525–36.

    Google Scholar 

  • Chen M, Liu Y, Cao Y, et al. Remodeling the Proinflammatory microenvironment in osteoarthritis through Interleukin-1 beta tailored exosome cargo for inflammatory regulation and cartilage regeneration. ACS Nano. 2025;19(4):4924–41.

    Google Scholar 

  • Duan A, Shen K, Li B, et al. Extracellular vesicles derived from LPS-preconditioned human synovial mesenchymal stem cells inhibit extracellular matrix degradation and prevent osteoarthritis of the knee in a mouse model. Stem Cell Res Ther. 2021;12(1):427.

    Google Scholar 

  • Molnar V, Matišić V, Kodvanj I, et al. Cytokines and chemokines involved in osteoarthritis pathogenesis. Int J Mol Sci. 2021;22(17):9208.

    Google Scholar 

  • Wu J, Wu J, Xiang W, et al. Engineering exosomes derived from TNF-α preconditioned IPFP-MSCs enhance both yield and therapeutic efficacy for osteoarthritis. J Nanobiotechnol. 2024;22(1):555.

    Google Scholar 

  • Yamamoto K, Troeberg L, Scilabra SD, et al. LRP-1-mediated endocytosis regulates extracellular activity of ADAMTS-5 in articular cartilage. FASEB J. 2013;27(2):511–21.

    Google Scholar 

  • Wang R, Xu B. TGF-β1-modified MSC-derived Exosomal miR-135b attenuates cartilage injury via promoting M2 synovial macrophage polarization by targeting MAPK6. Cell Tissue Res. 2021;384(1):113–27.

    Google Scholar 

  • Zhao T, Mu Y, Deng H, et al. Research hotspots and trends of mesenchymal stem cell-derived extracellular vesicles for drug delivery: a bibliometric and visualization analysis from 2013 to 2023. Front Cell Dev Biol. 2024;12:1412363.

    Google Scholar 

  • Hao D, Lopez JM, Chen J, et al. Engineering extracellular microenvironment for tissue regeneration. Bioeng (Basel). 2022;9(5):202.

    Google Scholar 

  • Weng Z, Zhang B, Wu C, et al. Therapeutic roles of mesenchymal stem cell-derived extracellular vesicles in cancer. J Hematol Oncol. 2021;14(1):136.

    Google Scholar 

  • Liang Y, Xu X, Li X, et al. Chondrocyte-Targeted MicroRNA delivery by engineered exosomes toward a Cell-Free osteoarthritis therapy. ACS Appl Mater Interfaces. 2020;12(33):36938–47.

    Google Scholar 

  • Xu X, Liang Y, Li X, et al. Exosome-mediated delivery of Kartogenin for chondrogenesis of synovial fluid-derived mesenchymal stem cells and cartilage regeneration. Biomaterials. 2021;269:120539.

    Google Scholar 

  • Liang Y, Xu X, Xu L, et al. Chondrocyte-specific genomic editing enabled by hybrid exosomes for osteoarthritis treatment. Theranostics. 2022;12(11):4866–78.

    Google Scholar 

  • Zhang H, Yan W, Wang J, et al. Surface functionalization of exosomes for chondrocyte-targeted SiRNA delivery and cartilage regeneration. J Control Release. 2024;369:493–505.

    Google Scholar 

  • Midekessa G, Godakumara K, Ord J, et al. Zeta potential of extracellular vesicles: toward Understanding the attributes that determine colloidal stability. ACS Omega. 2020;5(27):16701–10.

    Google Scholar 

  • Shamji MH, Boyle RJ. Adverse effects of Dupilumab, effects of peanut OIT on the gut Microbiome and allergy training in the united Kingdom. Clin Exp Allergy. 2025;55(5):364–6.

    Google Scholar 

  • Desai N, Rana D, Patel M, et al. Nanoparticle therapeutics in clinical perspective: Classification, marketed Products, and regulatory landscape. Small. 2025;21(29):e2502315.

    Google Scholar 

  • Zhang C, Pathrikar TV, Baby HM, et al. Charge-Reversed exosomes for targeted gene delivery to cartilage for osteoarthritis treatment. Small Methods. 2024;8(9):e2301443.

    Google Scholar 

  • Feng K, Xie X, Yuan J, et al. Reversing the surface charge of MSC-derived small extracellular vesicles by εPL-PEG-DSPE for enhanced osteoarthritis treatment. J Extracell Vesicles. 2021;10(13):e12160.

    Google Scholar 

  • Qiu B, Xu X, Yi P, Hao Y. Curcumin reinforces MSC-derived exosomes in attenuating osteoarthritis via modulating the miR-124/NF-kB and miR-143/ROCK1/TLR9 signalling pathways. J Cell Mol Med. 2020;24(18):10855–65.

    Google Scholar 

  • Zhang Y, Liu K, Ma X, et al. Therapeutic effects of puerarin loaded bone marrow mesenchymal stem Cell-Derived exosomes in a rat model of osteoarthritis. Chem Biodivers. 2025;22(3):e202402095.

    Google Scholar 

  • Tao Y, Zhou J, Wang Z, et al. Human bone mesenchymal stem cells-derived Exosomal miRNA-361-5p alleviates osteoarthritis by downregulating DDX20 and inactivating the NF-κB signaling pathway. Bioorg Chem. 2021;113:104978.

    Google Scholar 

  • Khan NA, Asim M, Biswas KH, et al. Exosome nanovesicles as potential biomarkers and immune checkpoint signaling modulators in lung cancer microenvironment: recent advances and emerging concepts. J Exp Clin Cancer Res. 2023;42(1):221.

    Google Scholar 

  • Xu X, Xu L, Wen C, Xia J, Zhang Y, Liang Y. Programming assembly of biomimetic exosomes: an emerging theranostic nanomedicine platform. Mater Today Bio. 2023;22:100760.

    Google Scholar 

  • Gulen MF, Samson N, Keller A, et al. cGAS-STING drives ageing-related inflammation and neurodegeneration. Nature. 2023;620(7973):374–80.

    Google Scholar 

  • Feng G, Wu Y, He X, et al. Lubricated hydrogel with STING-inhibiting exos protect the osteoarthritis by suppressing the senescent microenvironment. Nano Today. 2025;62:102688.

    Google Scholar 

  • Lagneau N, Tournier P, Nativel F, et al. Harnessing cell-material interactions to control stem cell secretion for osteoarthritis treatment. Biomaterials. 2023;296:122091.

    Google Scholar 

  • Cheng J, Sun Y, Ma Y, Ao Y, Hu X, Meng Q. Engineering of MSC-Derived exosomes: A promising Cell-Free therapy for osteoarthritis. Membr (Basel). 2022;12(8):739.

    Google Scholar 

  • Lu H, Zhang Y, Xiong S, et al. Modulatory role of silver nanoparticles and mesenchymal stem Cell-Derived Exosome-Modified barrier membrane on macrophages and osteogenesis. Front Chem. 2021;9:699802.

    Google Scholar 

  • Lei H, Cao H, Chen X, et al. A functionalized 3D-Printed Ti-6Al‐4V cell climbing frame inspired by marine sponges to recruit and rejuvenate autologous BMSCs in osteoporotic bone repair. Adv Mater. 2025;37(11):e2413238.

    Google Scholar 

  • Luo L, Zheng W, Li J, et al. 3D-Printed titanium trabecular scaffolds with sustained release of Hypoxia-Induced exosomes for Dual-Mimetic bone regeneration. Adv Sci (Weinh). 2025;12(23):e2500599.

    Google Scholar 

  • Fernandes JS, Gentile P, Pires RA, Reis RL, Hatton PV. Multifunctional bioactive glass and glass-ceramic biomaterials with antibacterial properties for repair and regeneration of bone tissue. Acta Biomater. 2017;59:2–11.

    Google Scholar 

  • Liu A, Lin D, Zhao H, et al. Optimized BMSC-derived osteoinductive exosomes immobilized in hierarchical scaffold via lyophilization for bone repair through Bmpr2/Acvr2b competitive receptor-activated Smad pathway. Biomaterials. 2021;272:120718.

    Google Scholar 

  • Bohner M, Santoni B, Döbelin N. β-tricalcium phosphate for bone substitution: synthesis and properties. Acta Biomater. 2020;113:23–41.

    Google Scholar 

  • Zhang J, Liu X, Li H, et al. Exosomes/tricalcium phosphate combination scaffolds can enhance bone regeneration by activating the PI3K/Akt signaling pathway. Stem Cell Res Ther. 2016;7(1):136.

    Google Scholar 

  • Zhang B, Huang J, Liu J, Lin F, Ding Z, Xu J. Injectable composite hydrogel promotes osteogenesis and angiogenesis in spinal fusion by optimizing the bone marrow mesenchymal stem cell microenvironment and exosomes secretion. Mater Sci Eng C Mater Biol Appl. 2021;123:111782.

    Google Scholar 

  • Garcia-Aponte OF, Kahlenberg S, Kouroupis D, Egger D, Kasper C. Effects of hydrogels on mesenchymal Stem/Stromal cells paracrine activity and extracellular vesicles production. J Extracell Vesicles. 2025;14(3):e70057.

    Google Scholar 

  • Cao H, Duan L, Zhang Y, Cao J, Zhang K. Current hydrogel advances in physicochemical and biological response-driven biomedical application diversity. Signal Transduct Target Ther. 2021;6(1):426.

    Google Scholar 

  • Guan P, Liu C, Xie D, et al. Exosome-loaded extracellular matrix-mimic hydrogel with anti-inflammatory property Facilitates/promotes growth plate injury repair. Bioact Mater. 2022;10:145–58.

    Google Scholar 

  • Li Q, Xu S, Feng Q, et al. 3D printed silk-gelatin hydrogel scaffold with different porous structure and cell seeding strategy for cartilage regeneration. Bioact Mater. 2021;6(10):3396–410.

    Google Scholar 

  • Lenzini S, Bargi R, Chung G, Shin JW. Matrix mechanics and water permeation regulate extracellular vesicle transport. Nat Nanotechnol. 2020;15(3):217–23.

    Google Scholar 

  • Zeng J, Sun P, Zhao Y, Fang X, Wu Z, Qi X. Bone mesenchymal stem cell-derived exosomes involved co-delivery and synergism effect with Icariin via mussel-inspired multifunctional hydrogel for cartilage protection. Asian J Pharm Sci. 2023;18(3):100799.

    Google Scholar 

  • Zheng Y, Fu L, Zhang Z, et al. Three-Dimensional Bioprinting of growth differentiation factor 5-Preconditioned mesenchymal stem Cell-Derived exosomes facilitates articular cartilage endogenous regeneration. ACS Nano. 2025;19(16):15281–301.

    Google Scholar 

  • Chen P, Zheng L, Wang Y, et al. Desktop-stereolithography 3D printing of a radially oriented extracellular matrix/mesenchymal stem cell exosome Bioink for osteochondral defect regeneration. Theranostics. 2019;9(9):2439–59.

    Google Scholar 

  • Li Q, Yu H, Zhao F, et al. 3D printing of Microenvironment-Specific bioinspired and Exosome-Reinforced hydrogel scaffolds for efficient cartilage and subchondral bone regeneration. Adv Sci (Weinh). 2023;10(26):e2303650.

    Google Scholar 

  • Tu C, Gao X, Zheng H, et al. Innovative injectable, self-healing, exosome cross-linked biomimetic hydrogel for cartilage regeneration. J Control Release. 2025;381:113608.

    Google Scholar 

  • Gao J, Xia Z, Mary HB, Joseph J, Luo JN, Joshi N. Overcoming barriers for intra-articular delivery of disease-modifying osteoarthritis drugs. Trends Pharmacol Sci. 2022;43(3):171–87.

    Google Scholar 

  • D’Souza N, Charlton J, Grayson J, et al. Are biomechanics during gait associated with the structural disease onset and progression of lower limb osteoarthritis? A systematic review and meta-analysis. Osteoarthritis Cartilage. 2022;30(3):381–94.

    Google Scholar 

  • Zhang X, Ma S, Naz SI, et al. Comprehensive characterization of pathogenic synovial fluid extracellular vesicles from knee osteoarthritis. Clin Immunol. 2023;257:109812.

    Google Scholar 

  • Chen P, Tang S, Gao H, et al. Wharton’s jelly mesenchymal stem cell-derived small extracellular vesicles as natural nanoparticles to attenuate cartilage injury via MicroRNA regulation. Int J Pharm. 2022;623:121952.

    Google Scholar 

  • Li L, Wang F, Zhu D, Hu S, Cheng K, Li Z. Engineering exosomes and exosome-like nanovesicles for improving tissue targeting and retention. Fundam Res. 2025;5(2):851–67.

    Google Scholar 

  • Li Y, Wang Y, Zhao H, Pan Q, Chen G. Engineering strategies of Plant-Derived Exosome-Like nanovesicles: current knowledge and future perspectives. Int J Nanomed. 2024;19:12793–815.

    Google Scholar 

  • Zhao B, Wei J, Jiang Z, et al. Mesenchymal stem cell-derived exosomes: an emerging therapeutic strategy for hepatic ischemia-reperfusion injury. Stem Cell Res Ther. 2025;16(1):178.

    Google Scholar 

  • Soland MA, Bego M, Colletti E, et al. Mesenchymal stem cells engineered to inhibit complement-mediated damage. PLoS ONE. 2013;8(3):e60461.

    Google Scholar 

  • Li Y, Chen F, Zhao W, et al. Harnessing extracellular vesicles from adipose-derived stem cells for the treatment of 4-vinylcyclohexene diepoxide-induced premature ovarian insufficiency. Stem Cell Res Ther. 2025;16(1):425.

    Google Scholar 

Continue Reading

  • Planar rotating permanent magnetic mechanical antenna array for beamforming

  • Bickford, J. A., McNabb, R. S., Ward, P. A., Freeman, D. K. & Weinberg, M.S. Low frequency mechanical antennas: Electrically short transmitters from mechanically-actuated dielectrics. In 2017 IEEE International Symposium on Antennas and Propagation & USNC/URSI National Radio Science Meeting 1475–1476 (2017).

  • Cui, Y. et al. ‘Extremely-low-frequency transmitter based on oscillating electret toward increasing data rate with low power consumption. IEEE Trans. Ind. Inform. 21(7), 5381–5389 (2025).

    Google Scholar 

  • Cui, Y., Wang, C., & Song, X., et al. A survey of mechanical antennas applied for low-frequency transmitting. iScience 26(1), (2023).

  • Bickford, J. A. et al. ‘Performance of electrically small conventional and mechanical antennas. IEEE Trans. Antenna. Propag. 67(4), 2209–2223 (2019).

    Google Scholar 

  • Cui, Y. et al. A directional pattern reconfigurable low-frequency antenna based on permanent magnet ARRAY. IEEE Trans. Antenna. Propag. 73(6), 3517–3526 (2025).

    Google Scholar 

  • Yang, S. et al. Long-range EM communication underwater with ultracompact ELF magneto-mechanical antenna. IEEE Trans. Antenna. Propag. 71(3), 2082–2097 (2023).

    Google Scholar 

  • Cui, Y. et al. A novel positioning method for UAV in GNSS-denied environments based on mechanical antenna. IEEE Trans. Ind. Electron. 71(10), 13461–13469 (2024).

    Google Scholar 

  • Zhang, J., Zhou, Q., He, X. & Liang, C. Super low frequency transmitting system based on mechanical antenna with horizontal rotating magnet array. In 2024 IEEE 10th International Symposium on Microwave, Antenna, Propagation and EMC Technologies for Wireless Communications (MAPE) 1–4 (2024).

  • Chen, Y. L. et al. 3-D positioning method of pipeline robots based on a rotating permanent magnet mechanical antenna. IEEE Sens. J 23(7), 7095–7104 (2023).

    Google Scholar 

  • He, X., Zhou, Q. & Zhang, J. Rotating magnet-based mechanical antenna for magnetic inductive communications. IEEE Trans. Antenna. Propag. 72(7), 5502–5510 (2024).

    Google Scholar 

  • Sun, F., Zhang, F., Ma, X., Ji, Y. & Fang, G. Rotating permanent magnet antenna array based on near-field polarization modulation. IEEE Antenna. Wirel. Propag. Lett. 21(6), 1193–1197 (2022).

    Google Scholar 

  • Wang, X., Yang, X., Li, Z., Zhang, B. & Cao, Z. Research on radiation field and driving based on super-low frequency mechanical antenna array. iScience 26(5), (2023).

  • Mysore Nagaraja, S.P. Directly Modulated Magnetic Pendulum Arrays for Efficient Ultra Low Frequency Transmission. Ph.D. (2020).

  • Srinivas Prasad, M. N. et al. ‘Magnetic pendulum arrays for efficient ULF transmission. Sci. Rep. 9(1), 13220 (2019).

    Google Scholar 

  • Mysore Nagaraja, S. P. et al. Magnetic pendulum arrays for efficient wireless power transmission. J. Phys. Conf. Ser. 1407(1), 012049 (2019).

    Google Scholar 

  • Srinivas, P. M. N., Tok, R. U., & Wang, Y. E. Magnetic pendulum arrays for ULF transmission. In 2018 IEEE International Symposium on Antennas and Propagation & USNC/URSI National Radio Science Meeting 71–72, (2018).

  • Manteghi, M. A navigation and positining system for unmanned underwater vehicles based on a mechanical antenna. In 2017 IEEE International Symposium on Antennas and Propagation & USNC/URSI National Radio Science Meeting 1997–1998 (2017).

    • Continue Reading

  • Oman signs agreement with Airbus for its first communications satellite

    Oman signs agreement with Airbus for its first communications satellite

    CAIRO, Nov 23 (Reuters) – Oman signed an agreement with Airbus on Sunday to design, manufacture and launch the sultanate’s first communications satellite, Oman’s state news agency reported.

    The new satellite would help boost Oman’s communications system and build capacities in areas of space and future technologies, the state news agency said.

    Sign up here.

    Reporting by Menna Alaa El-Din; Editing by Saad Sayeed

    Our Standards: The Thomson Reuters Trust Principles., opens new tab

    Continue Reading

  • Should Raymond James’ AI-Focused Upgrade Require Action From Doximity (DOCS) Investors?

    Should Raymond James’ AI-Focused Upgrade Require Action From Doximity (DOCS) Investors?

    • Earlier this week, Raymond James upgraded its rating on Doximity, emphasizing improved long-term growth potential and opportunities tied to artificial intelligence capabilities.

    • The analyst cited that Doximity’s recent focus on AI monetization and durable gains in market share could strengthen future revenue streams and company positioning.

    • Let’s explore how the emphasis on AI-driven monetization may reshape Doximity’s investment narrative and its outlook going forward.

    Find companies with promising cash flow potential yet trading below their fair value.

    To be a Doximity shareholder, you need to believe that its transition toward AI-powered healthcare workflow tools can unlock greater platform stickiness, deeper client relationships, and ultimately a durable source of growth and margin expansion. The recent Raymond James upgrade underscores renewed confidence in AI monetization, but it does not fundamentally change the key near-term catalyst: evidence of material revenue contribution from new AI features. The biggest current risk, ongoing reliance on pharmaceutical marketing budgets and potential regulatory pressures, remains largely unchanged by this news.

    Looking at the most recent Q2 FY2026 earnings report, Doximity posted meaningful year-over-year increases in both revenue and net income. While these results show continued business momentum, it’s too soon to see direct financial impact from newer AI-driven initiatives discussed in the Raymond James analysis. With AI monetization still an emerging factor, near-term expectations are best managed around core revenue streams and market share retention rather than immediate windfalls from new technology.

    However, in contrast to these positive signals around platform growth, investors should also keep in mind …

    Read the full narrative on Doximity (it’s free!)

    Doximity’s outlook anticipates $805.8 million in revenue and $280.5 million in earnings by 2028. This is based on analysts’ assumptions of 11.0% annual revenue growth and a $45.4 million earnings increase from the current earnings of $235.1 million.

    Uncover how Doximity’s forecasts yield a $71.11 fair value, a 41% upside to its current price.

    DOCS Community Fair Values as at Nov 2025

    Eight members of the Simply Wall St Community have fair value estimates for Doximity ranging from US$32.58 up to US$78.58. While some focus on expanding AI integration as a growth catalyst, others see substantial risk in the company’s exposure to pharmaceutical marketing cycles, reminding you to explore multiple viewpoints when forming expectations about future performance.

    Explore 8 other fair value estimates on Doximity – why the stock might be worth as much as 56% more than the current price!

    Disagree with existing narratives? Create your own in under 3 minutes – extraordinary investment returns rarely come from following the herd.

    • A great starting point for your Doximity research is our analysis highlighting 4 key rewards that could impact your investment decision.

    • Our free Doximity research report provides a comprehensive fundamental analysis summarized in a single visual – the Snowflake – making it easy to evaluate Doximity’s overall financial health at a glance.

    Don’t miss your shot at the next 10-bagger. Our latest stock picks just dropped:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include DOCS.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • Evaluating Valuation After Recent Share Price Pullback

    Evaluating Valuation After Recent Share Price Pullback

    Spotify Technology (NYSE:SPOT) has been navigating a challenging stretch in the market, with shares down over 16% in the past 3 months. Investors are taking stock of Spotify’s fundamentals and recent financial performance to gauge what could come next.

    See our latest analysis for Spotify Technology.

    Spotify’s share price has given back some recent gains, falling more than 16% over the last three months as investors weighed up future growth and risk. However, the backdrop remains strong with a 27.5% year-to-date price return and a 22.9% total shareholder return over the past year. Momentum appears to be cooling after a breakout period, yet the company’s long-term story is far from finished.

    If you’re watching for fresh ideas beyond streaming giants, this could be the right moment to expand your search and discover See the full list for free.

    With shares pulling back sharply while fundamentals remain upbeat, the question now is whether Spotify offers genuine value at these levels or if the market has already factored in all its potential for future growth.

    Spotify’s widely followed narrative, according to MichaelP, prices the stock’s fair value notably above its recent close, suggesting there may be more upside for those looking beyond recent volatility. The narrative’s fair value calculation points to an opportunity grounded in long-term cash generation rather than today’s headwinds.

    “The market’s obsession with short-term results over long-term results is what led many investors to misunderstand Amazon, Netflix and many others in their early days, and the same is true with Spotify. You’d hear investors say: ‘Yeah, but you aren’t profitable?’ Well, those companies were playing the long game while those investors who only looked a few quarters out missed the boat of companies that had great qualitative metrics that weren’t yet evident in traditional quantitative financial metrics.”

    Read the complete narrative.

    Curious what bold assumptions are fueling this premium? Fresh revenue strategies, rising margins, and ambitious user milestones are all in play, paving the way for a market-shaking target that challenges conventional thinking. The details may raise some eyebrows. Are you ready for the full story?

    Result: Fair Value of $703 (UNDERVALUED)

    Have a read of the narrative in full and understand what’s behind the forecasts.

    However, competition among global streaming platforms and slower-than-expected ad revenue growth could challenge Spotify’s path to sustained margin expansion and dominance.

    Find out about the key risks to this Spotify Technology narrative.

    Looking at Spotify through the lens of its price-to-earnings ratio, the picture changes. The company trades at 74.3x earnings, significantly higher than both the US Entertainment industry average of 19.4x and the peer average of 67.2x. This is also well above the fair ratio of 36.9x. This suggests investors are currently paying a premium for future growth. Could this signal greater risk if those high expectations are not met?

    See what the numbers say about this price — find out in our valuation breakdown.

    NYSE:SPOT PE Ratio as at Nov 2025

    Keep in mind that if you have a different perspective or prefer to dig into the numbers yourself, it takes less than three minutes to craft your own view. Do it your way.

    A good starting point is our analysis highlighting 4 key rewards investors are optimistic about regarding Spotify Technology.

    Don’t limit your portfolio to just the big names. Some of the most exciting opportunities are just a few clicks away in fast-growing sectors and hidden gems.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include SPOT.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading

  • UK’s big law firms risk losing talented staff over ‘unmanageable’ stress

    UK’s big law firms risk losing talented staff over ‘unmanageable’ stress

    Unlock the Editor’s Digest for free

    Two in five associates at big law firms in the UK plan to leave their jobs in the next five years because of stress and insufficient support from their employers in a trend that threatens to intensify a struggle to retain staff in an already competitive market.

    More than half the associates surveyed by legal rankings company Chambers and Partners said their stress levels were “unmanageable”, with senior associates — lawyers who have five years or more of post-qualification experience — the most unhappy cohort.

    Partners, whose pay has surged in recent years, were more positive, with 75 per cent stating they were happy in their role, according to the report shared with the Financial Times.

    The drivers of dissatisfaction varied between regional and national UK law firms, where pay was the main issue for junior lawyers, and at US-founded firms, whose employees mostly cited work-life balance and a lack of career development tools for their unhappiness.

    Chambers and Partners, which was acquired by US investment group Abry Partners in 2023, surveyed 1,680 lawyers working at 110 top law firms in the UK. The findings indicate that firms will have to work harder to retain their best employees after expansion by US firms in recent years sparked pay wars and high levels of staff turnover.

    Salaries for newly qualified lawyers (NQs) have increased dramatically while partner pay for top performers can reach tens of millions of dollars. The Financial Times reported in June that mid-tier firms had boosted pay for their most junior lawyers as they sought to keep up with bigger rivals.

    Pay increases for NQs and partners at the top have left senior associates frustrated, prompting some firms to seek to address this by freezing NQ pay to better reward more experienced associates.

    “Lawyers at the beginning of their careers report high levels of job satisfaction, but as they gain experience and move to associate level, happiness levels dip considerably, representing a significant flight risk,” said Lisa Hart Shepherd, chief product and innovation officer at Chambers and Partners.

    The survey found that there was only a small difference in the number of hours worked per week between the 55 per cent of associates who felt the stress of the job was unmanageable compared with those who did not.

    The main divergence was tied to how much the associates felt they were supported by partners and whether they thought their employers were invested in their future. Only 41 per cent of associates were satisfied with their firm’s efforts to support their wellbeing, the report found.

    While law firms are structured on the assumption that a “sizeable” proportion of junior recruits will leave before making partner, insufficient care for their wellbeing risks losing the ones they want to keep, said Laura Empson, a professor at Bayes Business School.

    “If half the associates find it unmanageable, the key question is: which half? Are the firms losing really good associates who, with greater care from their partners, could have developed into really good partners themselves?”

    Continue Reading

  • Oil majors return to Libya as Tripoli launches first exploration auction in 18 years

    Oil majors return to Libya as Tripoli launches first exploration auction in 18 years

    Stay informed with free updates

    The world’s biggest energy companies are returning to Libya as they hunt for new oil and gas reserves, nearly 15 years after the overthrow of Muammer Gaddafi pitched the country into political chaos that continues to this day. 

    A delegation from the Tripoli-based Libyan government has been visiting Washington this week to drum up interest in the country’s first auction of oil exploration licences for 18 years.

    Oil majors Shell, Chevron, TotalEnergies, Eni and Repsol are all pre-qualified to bid in the round that offers exploration rights across the country, after Exxon signed a deal in August to explore for gas off the Libyan coast.

    “We look forward to working with the Libya National Oil Corporation (NOC) to fully evaluate Libya’s potential and leverage ExxonMobil’s leading capabilities to jointly explore for new resources,” Exxon told the Financial Times. 

    The oil industry’s return to Libya started to gain momentum in July when Shell and BP confirmed they had signed agreements with the NOC to assess opportunities.

    The revived interest in the country, which remains divided between two rival governments and their affiliated armed groups, comes as energy companies seek to boost their reserves, after forecasts that crude demand would be stronger for longer because of a slower transition to clean energy.

    “They’re searching for more reserves and they’re returning to tried-and-tested basins,” said one senior energy banker, who added that oil majors were used to navigating politically risky environments. 

    The Tripoli government, which controls the west of the country, is keen to boost the country’s production from 1.4mn to 2mn barrels per day by 2030, and is offering new production sharing agreements to encourage investment.      

    “We’ve had discussions under way that have been reported in the media. So I can acknowledge this in Libya,” Mike Wirth, Chevron chief executive, told analysts at an investor day last week. “Terms are more attractive today than historically they have been,” he added.

    The Tripoli-based government is recognised by the UN but a large share of the country’s oil lies in the eastern territory held by the renegade general Khalifa Haftar.

    In Washington, the Libyan delegation has sought to convince the US that it can become a major supplier of oil and gas and that Tripoli needs US help to get Russia out of Libya and unify the country and its economy.

    Regional analysts have warned of a growing Russian military presence in the country’s east and south with corruption widespread across sectors. Moscow is a longtime backer of Haftar.

    “We have a problem,” Mahmoud Ahmed Alfiste, a senior Libyan official said during the delegation’s visit to Washington. While the world “recognises the NOC” as the only legitimate entity to “produce and export oil” from Libya, “Haftar and his sons are controlling” parts of the country that contain some critical reserves, Alfiste said.

    The Tripoli-based government believes the return of western oil companies across Libya could help boost Tripoli’s leverage and stabilise the country, officials said, while increased Libyan oil production would provide an alternative to Russian oil.

    “The US and western countries are trying to prevent Russia from selling its oil and its energy. That would bring a shortage in the energy market and Libya can be an alternative,” Ibrahim Sahed, another member of the delegation and of Libya’s High Council of State, told the FT. 

    He also said Libya needed western technology to enhance the production of its oilfields. “Nobody has technology like the US,” he said.

    Alfiste said the country’s petroleum ministry and NOC had already signed a memorandum of understanding with Chevron and was in discussions with ConocoPhillips.

    Tim Eaton, a Libya specialist at Chatham House in London, said the visit by a new US envoy earlier this year had helped attract interest. “If those companies are able to invest and build the oil sector, this can be a kind of rising tide that lifts all boats,” he said.

    But he warned that an influx of investments could entrench problems.

    “The risk is that these kinds of deals brokered via Libyan elites are going to solidify the status quo rather than provide an opportunity to transform it,” he said.

    Additional reporting by Jamie Smyth in New York

    Continue Reading

  • Major banks, including JPMorgan and Citi, warned of data exposure after hack, NYT reports

    Major banks, including JPMorgan and Citi, warned of data exposure after hack, NYT reports

    Information you can trust

    Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world’s media organizations, industry events and directly to consumers.

    Continue Reading

  • Public Service Enterprise Group (PEG) Declares Dividend of $0.63 per Share

    Public Service Enterprise Group (PEG) Declares Dividend of $0.63 per Share

    Public Service Enterprise Group Incorporated (NYSE:PEG) is included among the 14 Best Utility Dividend Stocks to Buy Now.

    Public Service Enterprise Group (PEG) Declares Dividend of $0.63 per Share

    Public Service Enterprise Group Incorporated (NYSE:PEG) is a predominantly regulated energy company that engages in the provision of electric and gas services.

    With a dividend history of 118 consecutive years, Public Service Enterprise Group Incorporated (NYSE:PEG) is known for its commitment to shareholders. On November 18, the company maintained this commitment by announcing a quarterly dividend of $0.63 per share to all shareholders as of the December 10 record date, payable on December 31, 2025.

    It needs mentioning that Public Service Enterprise Group Incorporated (NYSE:PEG) reported better-than-expected results for its third quarter earlier this month, witnessing a double-digit YoY growth in both revenue and profits, driven primarily by the implementation of new electric and gas base distribution rates that took effect in October 2024. As a result, the company narrowed its FY 2025 earnings guidance to $4 to $4.06 per share from $3.94 to $4.06 per share previously.

    Public Service Enterprise Group Incorporated (NYSE:PEG) also reaffirmed its adjusted operating earnings growth outlook of 5% to 7% through 2029, helped by its 5-year $22.5 billion – $26 billion capital investment program.

    While we acknowledge the potential of PEG as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

    READ NEXT: 10 Best Renewable Energy Dividend Stocks to Buy Now and 11 Best High Yield Energy Stocks to Buy Now.

    Disclosure: None.

    Continue Reading

  • A Look at SharpLink Gaming (SBET) Valuation Following Strong Sales Growth and Return to Profitability

    A Look at SharpLink Gaming (SBET) Valuation Following Strong Sales Growth and Return to Profitability

    SharpLink Gaming (SBET) released third-quarter earnings that caught investors’ attention, with sales rising to $10.84 million and a turnaround to net income compared to a loss during the same period last year.

    See our latest analysis for SharpLink Gaming.

    SharpLink Gaming’s third-quarter results have fueled a lot of talk, especially with the share price now at $9.52. While there’s still some volatility—the 1-day share price return jumped 2.37%, but the 30-day share price return is down 31.61%—the stock is actually up 17.83% year-to-date. For longer-term holders, the past year delivered a 16.67% total shareholder return, even as the three-year total return remains deeply negative, reminding investors that the momentum is building but the journey’s been a rollercoaster.

    If SharpLink’s rebound has your attention, it could be the perfect moment to broaden your perspective and discover fast growing stocks with high insider ownership

    Corrected version with em dashes replaced by better formatting:

    SharpLink Gaming’s third-quarter results have fueled a lot of talk, especially with the share price now at $9.52. While there is still some volatility, with the 1-day share price return jumping 2.37% but the 30-day share price return down 31.61%, the stock is actually up 17.83% year-to-date. For longer-term holders, the past year delivered a 16.67% total shareholder return. However, the three-year total return remains deeply negative, reminding investors that while momentum is building, the journey has been a rollercoaster.

    If SharpLink’s rebound has your attention, it could be the perfect moment to broaden your perspective and discover fast growing stocks with high insider ownership

    With SharpLink now trading well below analyst price targets despite its rapid revenue growth and recent return to profitability, the question is whether the stock offers hidden value or if the market has already accounted for future gains.

    SharpLink is trading on a price-to-book ratio of just 0.6x, while the industry average stands much higher at 2.4x, suggesting a notable discount at the current price of $9.52.

    The price-to-book ratio compares a company’s market value to its book value, revealing how much investors are willing to pay for each dollar of net assets. In sectors such as hospitality, where tangible assets play a significant role, this multiple can offer useful perspective on underlying value.

    With SharpLink’s price-to-book ratio well below industry peers (2.4x) and the broader peer group average (5x), the market appears to be heavily discounting the company’s potential. This type of gap often signals pessimism about future earnings, but it may also reflect the company’s young board and unproven earnings track record.

    SharpLink’s low valuation could point to overlooked growth catalysts or to deeper skepticism about management execution. If the price-to-book fair ratio becomes available, the market could shift rapidly toward a higher level.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-Book of 0.6x (UNDERVALUED)

    However, weak three-year total returns and limited profit history could challenge sustained enthusiasm if momentum stalls or if management execution disappoints.

    Find out about the key risks to this SharpLink Gaming narrative.

    Looking at SharpLink’s valuation from another angle, our DCF model suggests the stock is trading 32% below its estimated fair value of $14.02. This points to even greater upside than the price-to-book ratio alone suggests. However, can these models capture the full story?

    Look into how the SWS DCF model arrives at its fair value.

    SBET Discounted Cash Flow as at Nov 2025

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out SharpLink Gaming for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 926 undervalued stocks based on their cash flows. If you save a screener we even alert you when new companies match – so you never miss a potential opportunity.

    If you’re ready to dig deeper or think your perspective paints a different picture, know that creating your own analysis takes just a couple of minutes. Do it your way

    A great starting point for your SharpLink Gaming research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.

    Smart investors never settle on just one opportunity. Give yourself an edge and stay ahead by searching out unique stocks with real potential before everyone else catches on.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

    Companies discussed in this article include SBET.

    Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

    Continue Reading